Researchers rejected criticism of a recent study in an academic journal they co-authored from the leader of a 340B hospital [...] Read More »
Category: Research/Reports
Drug purchases under the 340B program totaled $53.7 billion in 2022, or 22.3% more than the $43.9 billion in 2021, [...] Read More »
Hospital 340B covered entity and child sites increased by more than 400% over the last 11 years, while the number [...] Read More »
The 340B program could more than double in size if the 340B patient definition expands, according to a recent report [...] Read More »
The proportion of retail contract pharmacies in the 340B program that contract exclusively with “core safety-net” facilities fell from 95% [...] Read More »
The 340B drug pricing program does not improve inpatient care quality for underserved patients, a recent government-funded analysis concluded. A [...] Read More »
The U.S. Government Accountability Office late last month restated its controversial recommendation that Congress take actions to reduce incentives for [...] Read More »
Hospitals charge, on average, 500% of their acquisition cost for 20 individual medicines that account for the largest share of [...] Read More »
A high-profile researcher and colleagues are urging a range of changes to the 340B program, including new provisions on transparency, [...] Read More »
As the not-for-profit hospital sector slowly emerges from its worst financial year in recent history, some of those organizations’ bottom [...] Read More »